
Hikal Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 4- Pharma division expects positive momentum with revenue and volume growth continuing into H2 FY25 and further improving in FY26, supported by new product launches and increased CDMO orders.
- Crop Protection division anticipates stabilization with volume growth recovering, expected to improve margins by H2 FY26 as excess inventory issues resolve.
- Overall, stronger H2 FY25 anticipated compared to H1 FY25; FY26 projected to be stronger than FY25.
- No specific forward-looking growth guidance provided due to uncertainty in Crop division.
- Company focused on capacity expansion in Pharma, with new capacity coming online next year (commercialization 1-2 years post-launch).
- Emphasis on acquiring new customers, technological advancements, and broadening geographic presence to drive sustainable, profitable growth.
See what Hikal management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No significant increase in debt is expected; the current debt level is comfortable.
- Debt has come down as of September compared to March.
- For FY25-26, INR130 crores of debt repayment is expected, and the company plans to maintain similar debt levels.
- Capex for the Pharma division will continue, partly funded by borrowing, but overall debt is expected to remain stable around INR800 crores.
- No mention of any planned equity fundraising in the disclosed communication.
See what Hikal management said on order book — free account, 30 seconds.
Capex plans
Yes- Hikal Limited is putting up new capacity primarily on the Pharma side, which will come on stream next year but will take 1-2 years to commercialize and become operational.
- The company continues to invest in assets in the Pharma division while maintaining a comfortable debt position.
- Capex plans primarily focus on the Pharma business.
- Debt is expected to stay around INR 800 crores with repayments planned (INR 130 crores in FY25-26).
- Hikal is expanding its front-end presence by onshoring personnel and setting up offices in North America, Europe, Japan, and Latin America to boost new business acquisition.
- Continuous R&D investment of about 4-5% of revenue is maintained to foster innovation and technology development.
- The strategic initiatives include Project Pinnacle aimed at profitable and sustainable growth across all segments.
Track Hikal — get its next earnings analysis in your feed
How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Hikal rank in Pharmaceuticals & Biotechnology?
Compare Hikal against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Hikal's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem